16 research outputs found
Masud T: A current update on osteonecrosis of the jaw and bisphosphonates. Dent Update 38
No full textAbstract: Bisphosphonates are effective drugs used to treat important medical conditions affecting the skeleton, such as malignancy and osteoporosis. Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is a rare but painful condition that can affect quality of life. Healthcare professionals need to be aware of this potential side-effect of bisphosphonates, as well as ways to minimize its occurrence. Clinical Relevance: This review addresses the definitions of BONJ, differential diagnosis and staging, prevention and also discusses a recently recognized non-exposed variant of BONJ. The possibility that a recently introduced anti-resorptive agent, denosumab, which is not a bisphosphonate, may cause jaw osteonecrosis is also discussed. Dent Update 2011; 38: 672-67
In apprehensione Petri Alfaro pro ipso , Da proposicion Pedro Alfaro, articulando entre Francisco Arrain y Isabel de Alfaro, se pactaron capitulos matrimoniales en los cuales Isabel Enrique da y manda a su hija 3800 libras ne contemplacion del matrimonio ...
No full textCopia digital : Diputación Provincial de Zaragoza. Servicio de Archivos y Bibliotecas, 2011Obra enc. junto con otras similares del S. XVIISign.: A\p4\sLetra capital tip
The risk of bisphosphonate-related osteonecrosis of the jaw in children. a case report and literature review
No full textThe characteristics of bisphosphonate patients developing bisphosphonate-related osteonecrosis of the jaw attending an OMFS department
No full textDenosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases
No full textEvaluation of an ICD-10 algorithm to detect osteonecrosis of the jaw among cancer patients in the Danish National Registry of Patients
No full textDenosumab, an alternative to bisphosphonates but also associated with osteonecrosis of the jaw – what is the risk?
No full textMost dental professionals will have, or will soon, encounter patients prescribed this novel alternative antiresorptive drug to bisphosphonates, denosumab (Prolia®, Xgeva®). Denosumab is licensed in the UK for the prevention of osteoporotic fractures in postmenopausal women and the prevention of skeletal-related events (SRE) in adults with bone metastases. The presence of osteonecrosis of the jaw in patients receiving non-bisphosphonate antiresorptives has led to the introduction of the term antiresorptive-related osteonecrosis of the jaw or ARONJ. This paper discusses the basic physiology of bone remodelling, the pharmacology of bisphosphonates and denosumab, and the risk of ARONJ
